« back

The Michael J. Fox Foundation for Parkinson’s Research: Pre-Clinical Therapeutics Pipeline Programme

  Sunday, 12 Feb 2023 | Funding Deadline

The Michael J. Fox Foundation is dedicated to finding a cure for Parkinson's disease through an aggressively funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's today.

The pre-clinical program seeks to accelerate the path of the therapeutic pipeline towards clinical results through the support of ambitious and scientifically robust pre-clinical studies aiming at developing and testing treatments and interventions that can address the unmet needs of people with PD.

Funding will support projects aimed at:

• Identifying, validating or developing novel pharmacological and non-pharmacological therapies through any of the pre-clinical stages of the therapeutics discovery and development process (addressing PD motor or non-motor symptoms, prevention of the disease and stopping or delaying disease progression).
• Testing repurposed or repositioned therapies addressing priority PD pathways and targets in pre-clinical PD models.

MJFF will prioritize proposals with the strongest preclinical-to-clinical translational potential, fulfilling the following criteria:

• Selected therapeutic target/pathway or mechanism shows a strong biological rationale to be pursued as a therapeutic target in PD.
• The proposal includes a translational biomarker development plan, including biomarkers to monitor target engagement/modulation, mechanism of action biomarkers, patient enrichment biomarkers etc. to de-risk clinical development.
• The applicant is either a company or an academic group in collaboration with an industry partner whose overall business plan aligns with the proposed research plan or has the ability and capacity to develop the potential therapeutic.

Deadline for proposals: 12 January 2023
Find out more here